financial guidance

The life science and diagnostics company's revenues were short of analyst expectations, though its earnings per share were in line with estimates.

The company beat analyst estimates for both revenues and earnings per share during the quarter, due largely to double-digit growth in its US business.

The company's quarterly revenue of $52.9 million blew away analyst estimates and its net loss of $.47 per share was better than analysts expected.

The company attributed the increase predominantly to a continued adoption of its infectious disease menu by US microbiology laboratories.

The company's quarterly revenue of $13.2 million and net loss of $.21 per share beat analysts' estimates. 

The company said revenues from its ConfirmMDx prostate cancer test rose 62 percent in 2015, and that testing volume exceeded 15,000 patients.

On an adjusted basis and at constant exchange rates, Q4 revenues increased about 3 percent year over year, but fell short of previously stated guidance of 5 percent growth.

The company's net earnings rose, and it reaffirmed its guidance of $195 million to $200 million in revenues for full year 2016.

Danaher's full-year revenues rose nearly 8 percent with its life sciences and diagnostics business its best-earning segment for both Q4 and FY2015.

The company projects revenues will rise 39 percent year over year in Q4, and 53 percent year over year for 2015.